论文部分内容阅读
目的了解再生障碍性贫血(再障)患者骨髓上清TNF-α,IFN-γ的水平,探讨其与免疫抑制剂环胞菌素A(CsA)治疗反应的关系。方法采用酶联免疫(ELISA法)对24例再障患者及20名正常人骨髓上清TNF-α,IFN-γ进行检测,所有再障患者给予CsA治疗至少3个月。结果再障病人骨髓上清TNF-α,IFN-γ水平与正常对照组比较均有明显统计学差异(P<0.05~0.01),TNF-α,IFN-γ水平高者对CsA治疗的反应好。结论再障患者骨髓上清TNF-α,IFN-γ水平较正常对照组均有不同程度的增高,对CsA治疗的反应可能与骨髓上清TNF-α,IFN-γ水平有关。
Objective To investigate the levels of TNF-α and IFN-γ in bone marrow supernatant of patients with aplastic anemia (aplastic anemia) and to investigate their relationship with the treatment of cyclosporine A (CsA). Methods Serum levels of TNF-α and IFN-γ in bone marrow from 24 patients with aplastic anemia and 20 normal controls were detected by enzyme-linked immunosorbent assay (ELISA). All patients with aplastic anemia received CsA for at least 3 months. Results The levels of TNF-α and IFN-γ in bone marrow supernatant of aplastic anemia patients were significantly different from those in normal control group (P <0.05-0.01). The patients with high levels of TNF-α and IFN-γ had good response to CsA . Conclusion The levels of TNF-α and IFN-γ in bone marrow supernatant of patients with aplastic anemia are higher than those in normal control group. The response to CsA therapy may be related to the levels of TNF-α and IFN-γ in bone marrow.